Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function

Carol B Toris, C. B. Camras, M. E. Yablonski, R. F. Brubaker

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Topical prostaglandins (PGs) are very effective at reducing intraocular pressure (IOP) in a variety of animals and in humans with relatively few side effects. The mechanisms of action of several PGs, their prodrugs and analogues have been studied in rabbits, cats, monkeys and humans. PGF(2α) and its analogues evaluated in monkeys include PGF(2α)-tromethamine salt, PGF(2α)-isopropylester (-IE), S-1033, PhXA34, PhDH100A and latanoprost (PhXA34). Aqueous flow and outflow facility are either increased or remain unchanged by these agents. PGF(2α)-IE, PHXA34, PhDH100A and latanoprost increase uveoscleral outflow, accounting for most of the IOP reduction. PGA2 in cats increases aqueous flow and outflow facility, but it reduces IOP primarily by stimulating uveoscleral outflow. The PGD2 analogue BW245C is unique in that it is the only PG that decreases aqueous flow. Mechanistic studies in humans have been performed with PGF(2α)-IE, unoprostone, PhXA34 and latanoprost. In two clinical studies with latanoprost, a significant increase in uveoscleral outflow was found which, as in animals, accounts for most of the IOP reduction. A slight but inconsistent increase in outflow facility may also be involved. The doses tested had minimal effects on the permeability of the blood-aqueous barrier (BAB). In vitro studies of human tissue have been conducted to elucidate the PG effect on outflow facility and uveoscleral outflow. Studies of isolated human anterior segment preparations show that PGE2 increases outflow facility whereas PGF(2α) has no measurable effect on this parameter. Studies of human ciliary muscle cells in tissue culture indicate that PGs may directly modulate extracellular matrix metabolism, which may be related to the increased uveoscleral drainage. This review summarizes in vitro and in vivo studies of the effects of PGs on aqueous humor dynamics and BAB integrity in humans, cats and monkeys.

Original languageEnglish (US)
JournalSurvey of Ophthalmology
Volume41
Issue numberSUPPL. 2
StatePublished - Jan 1 1997

Fingerprint

latanoprost
Blood-Aqueous Barrier
Aqueous Humor
Prostaglandins F
Prostaglandins
Intraocular Pressure
Haplorhini
Cats
S 1033
Prostaglandin D2
Tromethamine
Prodrugs
Dinoprostone
Muscle Cells
Extracellular Matrix
Drainage
Permeability

Keywords

  • aqueous humor dynamics
  • cat
  • human
  • latanoprost
  • monkey
  • outflow facility
  • prostaglandin
  • uveoscleral outflow

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function. / Toris, Carol B; Camras, C. B.; Yablonski, M. E.; Brubaker, R. F.

In: Survey of Ophthalmology, Vol. 41, No. SUPPL. 2, 01.01.1997.

Research output: Contribution to journalArticle

Toris, Carol B ; Camras, C. B. ; Yablonski, M. E. ; Brubaker, R. F. / Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function. In: Survey of Ophthalmology. 1997 ; Vol. 41, No. SUPPL. 2.
@article{fe3a02557d2d4cd8bddbe33d7d49227c,
title = "Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function",
abstract = "Topical prostaglandins (PGs) are very effective at reducing intraocular pressure (IOP) in a variety of animals and in humans with relatively few side effects. The mechanisms of action of several PGs, their prodrugs and analogues have been studied in rabbits, cats, monkeys and humans. PGF(2α) and its analogues evaluated in monkeys include PGF(2α)-tromethamine salt, PGF(2α)-isopropylester (-IE), S-1033, PhXA34, PhDH100A and latanoprost (PhXA34). Aqueous flow and outflow facility are either increased or remain unchanged by these agents. PGF(2α)-IE, PHXA34, PhDH100A and latanoprost increase uveoscleral outflow, accounting for most of the IOP reduction. PGA2 in cats increases aqueous flow and outflow facility, but it reduces IOP primarily by stimulating uveoscleral outflow. The PGD2 analogue BW245C is unique in that it is the only PG that decreases aqueous flow. Mechanistic studies in humans have been performed with PGF(2α)-IE, unoprostone, PhXA34 and latanoprost. In two clinical studies with latanoprost, a significant increase in uveoscleral outflow was found which, as in animals, accounts for most of the IOP reduction. A slight but inconsistent increase in outflow facility may also be involved. The doses tested had minimal effects on the permeability of the blood-aqueous barrier (BAB). In vitro studies of human tissue have been conducted to elucidate the PG effect on outflow facility and uveoscleral outflow. Studies of isolated human anterior segment preparations show that PGE2 increases outflow facility whereas PGF(2α) has no measurable effect on this parameter. Studies of human ciliary muscle cells in tissue culture indicate that PGs may directly modulate extracellular matrix metabolism, which may be related to the increased uveoscleral drainage. This review summarizes in vitro and in vivo studies of the effects of PGs on aqueous humor dynamics and BAB integrity in humans, cats and monkeys.",
keywords = "aqueous humor dynamics, cat, human, latanoprost, monkey, outflow facility, prostaglandin, uveoscleral outflow",
author = "Toris, {Carol B} and Camras, {C. B.} and Yablonski, {M. E.} and Brubaker, {R. F.}",
year = "1997",
month = "1",
day = "1",
language = "English (US)",
volume = "41",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function

AU - Toris, Carol B

AU - Camras, C. B.

AU - Yablonski, M. E.

AU - Brubaker, R. F.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Topical prostaglandins (PGs) are very effective at reducing intraocular pressure (IOP) in a variety of animals and in humans with relatively few side effects. The mechanisms of action of several PGs, their prodrugs and analogues have been studied in rabbits, cats, monkeys and humans. PGF(2α) and its analogues evaluated in monkeys include PGF(2α)-tromethamine salt, PGF(2α)-isopropylester (-IE), S-1033, PhXA34, PhDH100A and latanoprost (PhXA34). Aqueous flow and outflow facility are either increased or remain unchanged by these agents. PGF(2α)-IE, PHXA34, PhDH100A and latanoprost increase uveoscleral outflow, accounting for most of the IOP reduction. PGA2 in cats increases aqueous flow and outflow facility, but it reduces IOP primarily by stimulating uveoscleral outflow. The PGD2 analogue BW245C is unique in that it is the only PG that decreases aqueous flow. Mechanistic studies in humans have been performed with PGF(2α)-IE, unoprostone, PhXA34 and latanoprost. In two clinical studies with latanoprost, a significant increase in uveoscleral outflow was found which, as in animals, accounts for most of the IOP reduction. A slight but inconsistent increase in outflow facility may also be involved. The doses tested had minimal effects on the permeability of the blood-aqueous barrier (BAB). In vitro studies of human tissue have been conducted to elucidate the PG effect on outflow facility and uveoscleral outflow. Studies of isolated human anterior segment preparations show that PGE2 increases outflow facility whereas PGF(2α) has no measurable effect on this parameter. Studies of human ciliary muscle cells in tissue culture indicate that PGs may directly modulate extracellular matrix metabolism, which may be related to the increased uveoscleral drainage. This review summarizes in vitro and in vivo studies of the effects of PGs on aqueous humor dynamics and BAB integrity in humans, cats and monkeys.

AB - Topical prostaglandins (PGs) are very effective at reducing intraocular pressure (IOP) in a variety of animals and in humans with relatively few side effects. The mechanisms of action of several PGs, their prodrugs and analogues have been studied in rabbits, cats, monkeys and humans. PGF(2α) and its analogues evaluated in monkeys include PGF(2α)-tromethamine salt, PGF(2α)-isopropylester (-IE), S-1033, PhXA34, PhDH100A and latanoprost (PhXA34). Aqueous flow and outflow facility are either increased or remain unchanged by these agents. PGF(2α)-IE, PHXA34, PhDH100A and latanoprost increase uveoscleral outflow, accounting for most of the IOP reduction. PGA2 in cats increases aqueous flow and outflow facility, but it reduces IOP primarily by stimulating uveoscleral outflow. The PGD2 analogue BW245C is unique in that it is the only PG that decreases aqueous flow. Mechanistic studies in humans have been performed with PGF(2α)-IE, unoprostone, PhXA34 and latanoprost. In two clinical studies with latanoprost, a significant increase in uveoscleral outflow was found which, as in animals, accounts for most of the IOP reduction. A slight but inconsistent increase in outflow facility may also be involved. The doses tested had minimal effects on the permeability of the blood-aqueous barrier (BAB). In vitro studies of human tissue have been conducted to elucidate the PG effect on outflow facility and uveoscleral outflow. Studies of isolated human anterior segment preparations show that PGE2 increases outflow facility whereas PGF(2α) has no measurable effect on this parameter. Studies of human ciliary muscle cells in tissue culture indicate that PGs may directly modulate extracellular matrix metabolism, which may be related to the increased uveoscleral drainage. This review summarizes in vitro and in vivo studies of the effects of PGs on aqueous humor dynamics and BAB integrity in humans, cats and monkeys.

KW - aqueous humor dynamics

KW - cat

KW - human

KW - latanoprost

KW - monkey

KW - outflow facility

KW - prostaglandin

KW - uveoscleral outflow

UR - http://www.scopus.com/inward/record.url?scp=0030906585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030906585&partnerID=8YFLogxK

M3 - Article

VL - 41

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - SUPPL. 2

ER -